Axsome Therapeutics AXSM Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's shares (diluted)?
- Axsome Therapeutics (AXSM) reported shares (diluted) of 51.2M in Q1 2026.
- How has Axsome Therapeutics's shares (diluted) changed year-over-year?
- Axsome Therapeutics's shares (diluted) increased by 4.8% year-over-year, from 48.9M to 51.2M.
- What is the long-term trend for Axsome Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Axsome Therapeutics's shares (diluted) has grown at a 7.1% compound annual growth rate (CAGR), from 150.3M to 198.1M.
- What does shares (diluted) mean?
- The average number of shares including all potential future shares.
- How do you interpret shares (diluted)?
- Significant growth in this number relative to basic shares indicates a high volume of outstanding options or convertible debt.
- How does shares (diluted) compare across companies?
- Standardized metric for evaluating the potential dilution risk inherent in a company's capital structure.